Indonesian court limits pharma patent extensions

Patient advocates welcomed an Indonesian court’s decision that restricts pharmaceutical companies from repeatedly extending their patents on existing drugs, a practice known as “patent evergreening.” The ruling in Indonesia could encourage similar legal challenges in other countries.

Advocates believe the practice limits access to affordable medicines. The court’s decision signals a willingness to prioritize public health needs over extending pharmaceutical monopolies.